The Antihypertensive and Lipid Lowering treatment to prevent Heart Attack Trial (ALLHAT) is one of two current mega-trials (the other being the AngloScandinavian Cardiac Outcomes Study, ASCOT), with over 42 000 'high-risk' antihypertensive patients with two objectives: firstly, to assess whether the newer antihypertensive agents (amlodipine, lisinopril, and doxazosin) reduce the incidence of coronary artery disease (CAD) when compared with a diuretic (chlorthalidone); and secondly, whether statin therapy in hypertensive patients with moderate hypercholesterolaemia will reduce cardiac events compared with placebo. Patients were randomised to one of the above four antihypertensive agents, with a planned follow-up of 4 -8 years. 1 On 24 January, 2000, the independent review committee recommended termination of the doxazosin arm on account of a 25% higher rate of the combined cardiovascular disease (CVD), a major secondary end-point, when compared to the patients taking chlorthalidone. 2 The interim results were presented in March 2000 at the American College of Cardiology meeting in Anaheim, California, by Dr Barry Davis. The patients in both the doxazosin arm (n = 9067) and the chlorthalidone group (n = 15268) were very similar for baseline characteristics, and at 4 years, 86% of patients randomised to chlorthalidone were still taking the drug (vs 75% in the doxazosin arm). At 4 years, the mean systolic blood pressure was 135 mm Hg in the chlorthalidone group and 137 mm Hg in the doxazosin arm, with similar mean diastolic blood pressures. There was no difference in the relative risk (RR) of CAD between patients receiving doxazosin and those receiving chlorthalidone (RR 1.03; 95% CI 0.9-1.17), but the relative risk of combined CVD in the doxazosin arm compared with the chlorthalidone arm was 1.25 (95% CI 1.17-1.33; P Ͻ 0.0001), with the event curves diverging early. This effect was mainly related to an increased relative risk of heart failure in the patients taking doxazosin, Correspondence: Prof DG Beevers Received and accepted 24 March 2000 of 2.04 (95% CI 1.79-2.32), which was seen across gender, age, and ethnic subgroups. The relative risk for stroke was also increased in the doxazosin group (RR 1.19 (95% CI 1.01-1.14; P = 0.04)). Chlorthalidone, which is a much cheaper drug, therefore appeared superior to doxazosin for hypertension control, drug compliance, and reduction of cardiovascular complications.
Whilst the alpha blockers have been available for a great many years they have never been subjected to a long-term outcome trial in hypertension. In the short-term they seem attractive because not only do they lower blood pressure but they also have mildly beneficial effects on plasma lipid levels and also appear to improve insulin sensitivity. 3 The early alpha blocker, prazocin, was not popular because of a rapid first dose effect sometimes causing postural hypotension. Furthermore, it had to be given three times per day. 4 The arrival of doxazosin and its competitor terazosin seemed to be a major breakthrough. 5 Because of the lack of long-term outcome data of the use of doxazosin at first-line therapy, it is always tended to be a drug used in reserve for patients whose blood pressures are resistant to other therapies. For example in the ASCOT trial doxazosin is the third-line drug to add-in to either atenolol with bendrofluazide or perindopril with amlodipine. 6 There are also favourable reports of the use of doxazosin together with the angiotensin-converting enzyme (ACE) inhibitors. 7 The adverse effects of doxazosin appear until now to be related to symptomatic side-effects. The presence of alpha receptors at the bladder neck leads to relaxation of the urethra. This is a beneficial effect in men as it relieves the symptoms of benign prostatic hypertrophy. 8 Alpha blockers have already been used for this condition even in people who do not have high blood pressure. The effect however on the alpha-receptors in the bladder neck is disadvantageous in women and may lead to stress or urge incontinence. 9 Very occasionally patients do complain of what sounds like first dose hypotension and for that reason doxazosin is still often started with the first few doses to be taken at night. This precaution was absolutely necessary for patients receiv-ing prazosin but was hoped it would be less necessary for patients on doxazosin. The arrival of a longer acting gastrointestinal transfer system (GITS) formulation of doxazosin 8 mg was awaited with interest.
The adverse findings in the ALLHAT study must be looked at with caution at this stage. Clearly more information will become available. Indeed, the antihypertensive effect of doxazosin appears to be as good as that with the comparator drugs. In the Treatment of Mild Hypertension Study (TOMHS) doxazosin was equally effective as chlorthalidone, and had similar effects on echocardiographic left ventricular size. 10 In time we will perhaps learn whether the patients who were randomised to receive doxazosin in ALLHAT differed in any way from those randomised to the other drugs in respect of important baseline parameters such as left ventricular size or function.
Assuming that the adverse effects of doxazosin in ALLHAT are not due to confounding variables or systematic sources of bias, the next question is whether this adverse effect sounds plausible. What might the mechanisms be? In the past alpha blockers were considered as possible drugs for the treatment of heart failure and were not thought to be likely to cause it or to make it worse. 11 Whilst the difference between prazosin and placebo was not statistically significant, close examination of data on 642 men from the Vasodilator-Heart Failure Trial-1 (VeHFT-I) revealed 91 deaths (49.7%) in the prazosin group, compared to 120 deaths (44.0%) in those on placebo and 72 deaths (38.7%) in the hydralazine-nitrate group. 11 By reducing peripheral vascular resistance, the alpha-receptor blockers should reduce left ventricular after-load and therefore have effects which are beneficial and somewhat similar to those seen with ACE inhibitors or hydralazine with nitrates. 12 Short-term studies suggested that alpha blockers might have beneficial haemodynamic effects in patients with heart failure. [13] [14] [15] These findings however were mainly confined to patients receiving prazosin and not doxazosin.
It is generally considered that doxazosin has neutral effects on the renin-angiotensin system and does not cause any activation or suppression. 16 In that respect alpha blockers might seem more rather than less attractive than chlorthalidone which can cause a small shrinkage in plasma volume associated with a rise in plasma renin levels.
Clearly the doxazosin 'crisis' will be a source of much discussion in the coming months. We must be careful not to overreact. This is only one study showing this effect, albeit with tight confidence intervals, and it is possible that it might not be confirmed in future work. Secondly, it is possible that this might be a chance observation, although the 25% increase in relative risk of combined CVD in the doxazosin arm with a P value of Ͻ0.0001 seems convincing. We must not lose sight of the fact that in the ELITE I study losartan appeared to be better than captopril (although with a P value of only 0.035), but this was simply not confirmed in the much larger ELITE II study, which was presented at the American Heart Association meeting in November 1999. 17 It will be interesting to see whether the guidelines committees of the various National and International Hypertension Societies will modify their recommendations that alpha blockers can be used for first-line therapy. 18 It is certainly doubtful whether the alpha blockers should cease to be used as 'add-in' drugs where the first-line therapies have failed, because the hazards of uncontrolled hypertension may well override the possible hazard of alpha-blocking drugs.
